Cannabix and UBC are operating with each other to create marijuana breathalyzer technologies for a variety of markets
VANCOUVER, British Columbia, Sept. 23, 2019 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE:BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer is pleased to report that the Corporation has entered into an exclusive license agreement with the University of British Columbia (“UBC”) to use and commercialize specific technologies for the detection of volatile organic compounds for testing (to be utilised for marijuana breathalyzer purposes) owned by UBC created by Dr. Mina Hoofar and her group of researchers at the UBC Okanagan College of Engineering. The patent pending UBC technologies recognized as a “THC Breath Analyzer” (“THCBA”) incorporates hugely sensitive microfluidic sensors that can be manufactured at reasonably low price. This exclusive technologies license will let for Cannabix to present a complementary low-price transportable breathalyzer device that would be ideally suited for workplace, parental and individual use testing. Cannabix’s sophisticated “FAIMS” (field asymmetric waveform ion mobility spectrometry) primarily based marijuana breathalyzer program will be mainly focussed on roadside testing with law enforcement and toxicology lab confirmation. UBC is creating the THCBA on an accelerated pace and Cannabix anticipates that a breathalyzer device is anticipated to be out there for expanded testing this fall/winter. Important improvement operate has been achieved on the THCBA by UBC and pictures of the of the THCBA transportable device (below improvement) can be viewed at cannabixtechnologies.com (and are integrated in this press release).
The Corporation believes that the specialist requires of law enforcement customers (use at police stations and court acceptance) will probably differ from the requires of employers, and civilian customers of such devices. Specificity of use, pricing, ruggedization, disposables and calibration needs will all be variables in delivering many breathalyzer merchandise that meet the requires of certain consumers. The THCBA technologies will present a reasonably low-price option to the specialist grade selectivity and sensitivity supplied by the Cannabix FAIMS marijuana breathalyzer. Cannabix’s FAIMS device permits for mass spectrometry (MS) laboratory confirmation with its exceptional capacity to couple straight to MS. With each devices becoming created by Cannabix, the Corporation aims to drastically expand its prospective base of consumers for its merchandise and solutions.
Rav Mlait, CEO of Cannabix stated, “We are really excited about this chance to add this complementary technologies license to our solution portfolio. The joint UBC-Cannabix collaboration on this low-price marijuana breath testing technologies will facilitate our technique to greater segment market place possibilities with many devices. The marijuana breathalyzer technologies universe is in its early stages, and it is strategically vital for Cannabix to commercialize technologies that can bolster its capacity to present a variety of merchandise to meet the requires of various buyer segments. We think that diversifying our technologies holdings will be vital as regulators worldwide start to recognize the various forms of cannabis breathalyzer/detection technologies that are emerging. We want to be effectively ready to meet evolving evidentiary regulatory requirements for drug breath testing technologies.”
Dr. Mina Hoofar stated, “It is generally thrilling to see our investigation, that originates on the Okanagan campus of UBC, extend to the subsequent stage of improvement. We are thrilled that by means of this collaboration, devices will quickly enter the market place for self-monitoring and usage as a marijuana breathalyzer. This collaboration will bring our findings to market place giving customers with very affordable, transportable, rapid and precise devices. Collaborating with Cannabix suggests that we can leverage their knowledge in marketing and advertising and implementation, bringing the THC Breath Analyzer one particular step closer to getting into the market place. We appear forward to future collaborations with Cannabix as we continue to strive for innovation in the fields of micro-fluidics and bio-marker evaluation.”
The Corporation also reports granting two million incentive stock alternatives exercisable at $.80 cents per share for 5 years to officers and directors and two years for consultants.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a leader in marijuana breathalyzer improvement for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing transportable tools to market place to boost detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in numerous jurisdictions globally. Cannabix is operating to create drug-testing devices that will detect THC- the psychoactive element of marijuana that causes intoxication- utilizing breath samples. In unique, Cannabix is focused on creating breath testing devices for detection of current use of THC, in contrast to urine testing for THC metabolite that needs an invasive collection and reflects usage, days or even weeks earlier. The devices will also be helpful for other sensible applications such as testing staff in the workplace exactly where impairment by THC can be hazardous and for individual use testing.
We seek Protected Harbor.
On behalf of the Board of Directors
Cannabix Technologies Inc.
For additional details, make contact with the Corporation at [email protected]
The CSE has not reviewed and does not accept duty for the adequacy or accuracy of this release.
Cautionary Statement With regards to Forward-Searching Statements
This press release includes forward-hunting details that entails different dangers and uncertainties concerning future events. Such forward-hunting details can include things like devoid of limitation statements primarily based on existing expectations involving a quantity of dangers and uncertainties and are not guarantees of future efficiency of the Corporation, such as final improvement of a industrial or prototype solution(s), prosperous trial or pilot of corporation technologies, no assurance that industrial sales of any sort essentially materialize no assurance the Corporation will have enough funds to full solution improvement. There are a lot of dangers and uncertainties that could trigger actual outcomes and the Company’s plans and objectives to differ materially from these expressed in the forward-hunting details, which includes: (i) adverse market place circumstances (ii) dangers concerning protection of proprietary technologies (iii) the capacity of the Corporation to full financings (iv) the capacity of the Corporation to create and market place its future solution and (v) dangers concerning government regulation, managing and preserving development, the impact of adverse publicity, litigation, competitors and other variables which might be identified from time to time in the Company’s public announcements and filings. There is no assurance that the marijuana breathalyzer small business will give any advantage to the Corporation, and no assurance that any proposed new merchandise will be constructed or proceed. There is no assurance that current “patent pending” technologies licensed by the Corporation will acquire patent status by regulatory authorities. The Corporation is not presently promoting industrial breathalyzers. Actual outcomes and future events could differ materially from these anticipated in such details. These and all subsequent written and oral forward-hunting details are primarily based on estimates and opinions of management on the dates they are produced and are expressly certified in their entirety by this notice. Except as essential by law, the Corporation does not intend to update these forward-hunting statements.
Pictures accompanying this announcement are out there at: